Givosiran

From Wikipedia, the free encyclopedia

Givosiran
Clinical data
Trade namesGivlaari
AHFS/Drugs.comMonograph
License data
Routes of
administration
Subcutaneous
ATC code
Legal status
Legal status
Identifiers
  • N-[1,3-bis[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]-2-[[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]methyl]propan-2-yl]-12-[(2R,4R)-4-hydroxy-2-methylpyrrolidin-1-yl]-12-oxododecanamide
CAS Number
PubChem CID
DrugBank
UNII
KEGG
Chemical and physical data
FormulaC524H694F16N173O316P43S6
Molar mass16300.42 g·mol−1
3D model (JSmol)
  • C[C@@H]1C[C@H](CN1C(=O)CCCCCCCCCCC(=O)NC(COCCC(=O)NCCCNC(=O)CCCCO[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O)NC(=O)C)(COCCC(=O)NCCCNC(=O)CCCCO[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O)NC(=O)C)COCCC(=O)NCCCNC(=O)CCCCO[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)NC(=O)C)O
  • InChI=1S/C78H139N11O30/c1-50-42-54(96)43-89(50)65(104)26-12-10-8-6-5-7-9-11-25-64(103)88-78(47-111-39-27-61(100)82-33-19-30-79-58(97)22-13-16-36-114-75-66(85-51(2)93)72(108)69(105)55(44-90)117-75,48-112-40-28-62(101)83-34-20-31-80-59(98)23-14-17-37-115-76-67(86-52(3)94)73(109)70(106)56(45-91)118-76)49-113-41-29-63(102)84-35-21-32-81-60(99)24-15-18-38-116-77-68(87-53(4)95)74(110)71(107)57(46-92)119-77/h50,54-57,66-77,90-92,96,105-110H,5-49H2,1-4H3,(H,79,97)(H,80,98)(H,81,99)(H,82,100)(H,83,101)(H,84,102)(H,85,93)(H,86,94)(H,87,95)(H,88,103)/t50-,54-,55-,56-,57-,66-,67-,68-,69+,70+,71+,72-,73-,74-,75-,76-,77-/m1/s1
  • Key:RUPXJRIDSUCQAN-PQNNUJSWSA-N

Givosiran, sold under the brand name Givlaari, is a medication used for the treatment of adults with acute hepatic porphyria.[2][3][4][5] Givosiran is a small interfering RNA (siRNA) directed towards delta-aminolevulinate synthase 1 (ALAS1),[6] an important enzyme in the production of heme.

The most common side effects include nausea and injection site reactions.[5]

The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[7]

Medical uses[edit]

Givosiran is indicated for the treatment of adults with acute hepatic porphyria, a genetic disorder resulting in the buildup of toxic porphyrin molecules which are formed during the production of heme (which helps bind oxygen in the blood).[2][4]

History[edit]

In November 2019, givosiran was approved in the United States for the treatment of adults with acute hepatic porphyria (AHP).[4][8]

Efficacy was evaluated in ENVISION (NCT03338816), a randomized, double‑blind, placebo‑controlled, multinational trial enrolling 94 participants with acute hepatic porphyria.[5] Participants were randomized (1:1) to receive once monthly subcutaneous injections of givosiran 2.5 mg/kg or placebo during a six‑month double‑blind period.[5] The performance of givosiran was measured by the rate of porphyria attacks that required hospitalizations, urgent health care visits or intravenous infusion of hemin at home.[4] Participants who received givosiran experienced 70% fewer porphyria attacks compared to patients receiving a placebo.[4]

The U.S. Food and Drug Administration (FDA) granted the application for givosiran breakthrough therapy designation, priority review designation, and orphan drug designation.[4][5] The FDA granted the approval of Givlaari to Alnylam Pharmaceuticals.[4]

References[edit]

  1. ^ "Summary Basis of Decision (SBD) for Givlaari". Health Canada. 23 October 2014. Retrieved 29 May 2022.
  2. ^ a b c "Givlaari- givosiran sodium injection, solution". DailyMed. Retrieved 7 February 2022.
  3. ^ Syed YY (May 2021). "Givosiran: A Review in Acute Hepatic Porphyria". Drugs. 81 (7): 841–848. doi:10.1007/s40265-021-01511-3. PMID 33871817. S2CID 233292573.
  4. ^ a b c d e f g "FDA approves first treatment for inherited rare disease". U.S. Food and Drug Administration (FDA) (Press release). 20 November 2019. Archived from the original on 21 November 2019. Retrieved 20 November 2019. Public Domain This article incorporates text from this source, which is in the public domain.
  5. ^ a b c d e "FDA approves givosiran for acute hepatic porphyria". U.S. Food and Drug Administration (FDA). 20 November 2019. Archived from the original on 21 November 2019. Retrieved 20 November 2019. Public Domain This article incorporates text from this source, which is in the public domain.
  6. ^ Balwani M, Sardh E, et al.; ENVISION Investigators. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. N Engl J Med. 2020 Jun 11;382(24):2289-2301. doi: 10.1056/NEJMoa1913147. PMID 32521132.
  7. ^ "New Drug Therapy Approvals 2019". U.S. Food and Drug Administration. 31 December 2019. Retrieved 15 September 2020.
  8. ^ "Drug Trials Snapshots: Givlaari". U.S. Food and Drug Administration (FDA). 20 November 2019. Retrieved 24 January 2020. Public Domain This article incorporates text from this source, which is in the public domain.

External links[edit]